Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4911691 | 0.98 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL5430419 | 0.88 | HRH1 (0.47) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL7360165 | 0.86 | LOXL2 (0.54) | ALDH1A1LOXL2KDM4EGLASMN1; SMN2 | |
| SCHEMBL13102158 | 0.85 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4421244 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL2185893 | 0.80 | SIGMAR1 (0.68) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL18935640 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL40732 | 0.79 | — | — | |
| SCHEMBL13351099 | 0.78 | LOXL2 (0.46) | ALDH1A1LOXL2KDM4EGLASMN1; SMN2 | |
| SCHEMBL20689752 | 0.78 | SIGMAR1 (0.59) | ALDH1A1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018089695-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| EP-1934238-B1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| WO-2008143729-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008106226-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106224-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
| EP-1272468-B1 | INDOLIN-2-ONE DERIVATIVES, PREPARATION AND THEIR USE AS OCYTOCIN RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2004-03-25 | — | — | US | disclosed |
| US-6673790-B1 | ANTAGONIST OF OXYTOCIN RECEPTORS USED IN COMBINATION WITH ANTAGONIST OF VASOPRESSIN V1A RECEPTORS FOR TREATMENT OF DYSMENORRHEA OR ENDOMETRIOSIS OR CONTROL OF PREMATURE LABOR AND FOR CONTROLLING PREPARATORY LABOR FOR CAESAREAN DELIVERY | SANOFI-SYNTHELABO (FR) | 2004-01-06 | — | — | US | disclosed |
| US-3980788-A | XANTHENYL COMPOUNDS | SMITHKLINE CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | OXTR, AVPR2, AVPR1B | ALDH1A1 4188/4885LMNA 3205/4885HTT 2019/4885 |
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | OXTR, AVPR2, AVPR1B | ALDH1A1 4275/4885LMNA 3258/4885HTT 2086/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885LMNA 2494/4885HTT 4504/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885LMNA 2995/4885HTT 1684/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | ALDH1A1 4038/4885LMNA 2367/4885HTT 3931/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | ALDH1A1 813/4885LMNA 3545/4885HTT 331/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | ALDH1A1 3532/4885LMNA 2995/4885HTT 1684/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | ALDH1A1 543/4885LMNA 1627/4885HTT 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.